Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: A multicentric analysis (PAULA-1)

Alessandra Arcelli; Alessandra Guido; Milly Buwenge; Nicola Simoni; Renzo Mazzarotto; Gabriella Macchia; Francesco Deodato; Savino Cilla; Pierluigi Bonomo; Valerio Scotti; Liliana Belgioia; Giorgio Tolento; Francesco Cellini; Elisa Grassi; Mariacristina Di Marco; Riccardo Casadei; Alessio G. Morganti; Alessio Giuseppe Morganti; Silvia Cammelli

doi:10.21873/anticanres.13975

Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: A multicentric analysis (PAULA-1)

Alessandra Arcelli, Alessandra Guido, Milly Buwenge, Nicola Simoni, Renzo Mazzarotto, Gabriella Macchia, Francesco Deodato, Savino Cilla, Pierluigi Bonomo, Valerio Scotti, Liliana Belgioia, Giorgio Tolento, Francesco Cellini, Elisa Grassi, Mariacristina Di Marco, Riccardo Casadei, Alessio G. Morganti, Alessio Giuseppe Morganti, Silvia Cammelli

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

Aim: The purpose of the present multicentric study was to review stereotactic body radiotherapy (SBRT) with or without chemotherapy (CHT) experience in locally advanced pancreatic cancer (LAPC). Endpoints were overall survival (OS), local control (LC), and distant metastasis-free survival (DMFS). Several parameters’ impact on these outcomes was assessed. Materials and Methods: Fifty-six patients with LAPC undergoing SBRT+/-CHT were included. SBRT median BEDα/β10Gy was 48.0 Gy (range=28.0-78.7). Survival curves were calculated by Kaplan-Meier method. A Cox regression model was fitted. Results: At a median follow-up of 15.0 months, 2-year OS, LC, DMFS were: 33.8% 55.4%, and 22.9%, respectively. Patients treated with BEDα/β10Gy≥48 Gy showed improved OS (p=0.020) and LC (p=0.024). At multivariate analysis, BEDα/β10Gy≥48 Gy was significantly associated to both higher OS (p=0.042) and LC (p=0.045), while post-SBRT CHT improved DMFS (p=0.003). Conclusion: SBRT proved to be tolerable and effective in LAPC. Moreover, BEDα/β10Gy≥48 Gy was significantly correlated with improved OS and LC.

Lingua originale	English
pagine (da-a)	465-472
Numero di pagine	8
Rivista	Anticancer Research
Volume	40
DOI	https://doi.org/10.21873/anticanres.13975
Stato di pubblicazione	Pubblicato - 2020

Keywords

Adult
Aged
Aged, 80 and over
Chemotherapy
Disease-Free Survival
Dose effect
Dose-Response Relationship, Radiation
Female
Humans
Male
Middle Aged
Pancreatic Neoplasms
Pancreatic cancer
Radiosurgery
Stereotactic body radiotherapy
Survival Analysis

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.21873/anticanres.13975

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Arcelli, A., Guido, A., Buwenge, M., Simoni, N., Mazzarotto, R., Macchia, G., Deodato, F., Cilla, S., Bonomo, P., Scotti, V., Belgioia, L., Tolento, G., Cellini, F., Grassi, E., Di Marco, M., Casadei, R., Morganti, A. G., Morganti, A. G., & Cammelli, S. (2020). Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: A multicentric analysis (PAULA-1). Anticancer Research, 40, 465-472. https://doi.org/10.21873/anticanres.13975

@article{bbf9c707ce73452c844aaa3c702934a2,

title = "Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: A multicentric analysis (PAULA-1)",

abstract = "Aim: The purpose of the present multicentric study was to review stereotactic body radiotherapy (SBRT) with or without chemotherapy (CHT) experience in locally advanced pancreatic cancer (LAPC). Endpoints were overall survival (OS), local control (LC), and distant metastasis-free survival (DMFS). Several parameters{\textquoteright} impact on these outcomes was assessed. Materials and Methods: Fifty-six patients with LAPC undergoing SBRT+/-CHT were included. SBRT median BEDα/β10Gy was 48.0 Gy (range=28.0-78.7). Survival curves were calculated by Kaplan-Meier method. A Cox regression model was fitted. Results: At a median follow-up of 15.0 months, 2-year OS, LC, DMFS were: 33.8% 55.4%, and 22.9%, respectively. Patients treated with BEDα/β10Gy≥48 Gy showed improved OS (p=0.020) and LC (p=0.024). At multivariate analysis, BEDα/β10Gy≥48 Gy was significantly associated to both higher OS (p=0.042) and LC (p=0.045), while post-SBRT CHT improved DMFS (p=0.003). Conclusion: SBRT proved to be tolerable and effective in LAPC. Moreover, BEDα/β10Gy≥48 Gy was significantly correlated with improved OS and LC.",

keywords = "Adult, Aged, Aged, 80 and over, Chemotherapy, Disease-Free Survival, Dose effect, Dose-Response Relationship, Radiation, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Pancreatic cancer, Radiosurgery, Stereotactic body radiotherapy, Survival Analysis, Adult, Aged, Aged, 80 and over, Chemotherapy, Disease-Free Survival, Dose effect, Dose-Response Relationship, Radiation, Female, Humans, Male, Middle Aged, Pancreatic Neoplasms, Pancreatic cancer, Radiosurgery, Stereotactic body radiotherapy, Survival Analysis",

author = "Alessandra Arcelli and Alessandra Guido and Milly Buwenge and Nicola Simoni and Renzo Mazzarotto and Gabriella Macchia and Francesco Deodato and Savino Cilla and Pierluigi Bonomo and Valerio Scotti and Liliana Belgioia and Giorgio Tolento and Francesco Cellini and Elisa Grassi and {Di Marco}, Mariacristina and Riccardo Casadei and Morganti, {Alessio G.} and Morganti, {Alessio Giuseppe} and Silvia Cammelli",

year = "2020",

doi = "10.21873/anticanres.13975",

language = "English",

volume = "40",

pages = "465--472",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research:John G Delinassios, 1st Km Kapandritiou-Kalamou Road, Kapandriti Attiki 19014 Greece:011 30 2 2950 53389, 011 30 2950 52945, EMAIL: journals@iiar-anticancer.org, INTERNET: http://www.iiar-anticancer.org, Fax: 011 30 2 2950 53389, 011 30 2 2950 52945",

}

Arcelli, A, Guido, A, Buwenge, M, Simoni, N, Mazzarotto, R, Macchia, G, Deodato, F, Cilla, S, Bonomo, P, Scotti, V, Belgioia, L, Tolento, G, Cellini, F, Grassi, E, Di Marco, M, Casadei, R, Morganti, AG, Morganti, AG & Cammelli, S 2020, 'Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: A multicentric analysis (PAULA-1)', Anticancer Research, vol. 40, pagg. 465-472. https://doi.org/10.21873/anticanres.13975

TY - JOUR

T1 - Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: A multicentric analysis (PAULA-1)

AU - Arcelli, Alessandra

AU - Guido, Alessandra

AU - Buwenge, Milly

AU - Simoni, Nicola

AU - Mazzarotto, Renzo

AU - Macchia, Gabriella

AU - Deodato, Francesco

AU - Cilla, Savino

AU - Bonomo, Pierluigi

AU - Scotti, Valerio

AU - Belgioia, Liliana

AU - Tolento, Giorgio

AU - Cellini, Francesco

AU - Grassi, Elisa

AU - Di Marco, Mariacristina

AU - Casadei, Riccardo

AU - Morganti, Alessio G.

AU - Morganti, Alessio Giuseppe

AU - Cammelli, Silvia

PY - 2020

Y1 - 2020

N2 - Aim: The purpose of the present multicentric study was to review stereotactic body radiotherapy (SBRT) with or without chemotherapy (CHT) experience in locally advanced pancreatic cancer (LAPC). Endpoints were overall survival (OS), local control (LC), and distant metastasis-free survival (DMFS). Several parameters’ impact on these outcomes was assessed. Materials and Methods: Fifty-six patients with LAPC undergoing SBRT+/-CHT were included. SBRT median BEDα/β10Gy was 48.0 Gy (range=28.0-78.7). Survival curves were calculated by Kaplan-Meier method. A Cox regression model was fitted. Results: At a median follow-up of 15.0 months, 2-year OS, LC, DMFS were: 33.8% 55.4%, and 22.9%, respectively. Patients treated with BEDα/β10Gy≥48 Gy showed improved OS (p=0.020) and LC (p=0.024). At multivariate analysis, BEDα/β10Gy≥48 Gy was significantly associated to both higher OS (p=0.042) and LC (p=0.045), while post-SBRT CHT improved DMFS (p=0.003). Conclusion: SBRT proved to be tolerable and effective in LAPC. Moreover, BEDα/β10Gy≥48 Gy was significantly correlated with improved OS and LC.

AB - Aim: The purpose of the present multicentric study was to review stereotactic body radiotherapy (SBRT) with or without chemotherapy (CHT) experience in locally advanced pancreatic cancer (LAPC). Endpoints were overall survival (OS), local control (LC), and distant metastasis-free survival (DMFS). Several parameters’ impact on these outcomes was assessed. Materials and Methods: Fifty-six patients with LAPC undergoing SBRT+/-CHT were included. SBRT median BEDα/β10Gy was 48.0 Gy (range=28.0-78.7). Survival curves were calculated by Kaplan-Meier method. A Cox regression model was fitted. Results: At a median follow-up of 15.0 months, 2-year OS, LC, DMFS were: 33.8% 55.4%, and 22.9%, respectively. Patients treated with BEDα/β10Gy≥48 Gy showed improved OS (p=0.020) and LC (p=0.024). At multivariate analysis, BEDα/β10Gy≥48 Gy was significantly associated to both higher OS (p=0.042) and LC (p=0.045), while post-SBRT CHT improved DMFS (p=0.003). Conclusion: SBRT proved to be tolerable and effective in LAPC. Moreover, BEDα/β10Gy≥48 Gy was significantly correlated with improved OS and LC.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Chemotherapy

KW - Disease-Free Survival

KW - Dose effect

KW - Dose-Response Relationship, Radiation

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Pancreatic Neoplasms

KW - Pancreatic cancer

KW - Radiosurgery

KW - Stereotactic body radiotherapy

KW - Survival Analysis

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Chemotherapy

KW - Disease-Free Survival

KW - Dose effect

KW - Dose-Response Relationship, Radiation

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Pancreatic Neoplasms

KW - Pancreatic cancer

KW - Radiosurgery

KW - Stereotactic body radiotherapy

KW - Survival Analysis

UR - http://hdl.handle.net/10807/203480

U2 - 10.21873/anticanres.13975

DO - 10.21873/anticanres.13975

M3 - Article

SN - 0250-7005

VL - 40

SP - 465

EP - 472

JO - Anticancer Research

JF - Anticancer Research

ER -

Higher biologically effective dose predicts survival in SBRT of pancreatic cancer: A multicentric analysis (PAULA-1)

Abstract

Keywords

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo